Compare BIO-TECHNE Corp (TECH) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs VanEck Vietnam ETF — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while VanEck Vietnam ETF trades at $17.61. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while VanEck Vietnam ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| TECH | VNM | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | Sector/Thematic |
52-Week High | $72.29 | $19.80 |
52-Week Low | $43.31 | $16.34 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
VNM trades at $17.44, showing minimal daily change. Technical indicators are bullish overall, with moving averages signaling strength, while oscillators remain neutral. Key support and resistance levels are tightly clustered around $17 and $18. Recent news highlights regional capital flows and Vietnam-specific challenges, including power grid strain and FTSE Russell's emerging market reclassification affecting the ETF's performance.
The outlook is mixed, with technical strength countered by fundamental data gaps and external risks. Investment opportunity hinges on Vietnam's economic trajectory and foreign investment inflows, but risks include macroeconomic pressures and domestic infrastructure issues. Clarity on financial metrics is essential for a complete assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
